全文获取类型
收费全文 | 2213861篇 |
免费 | 170237篇 |
国内免费 | 7344篇 |
专业分类
耳鼻咽喉 | 29676篇 |
儿科学 | 71154篇 |
妇产科学 | 59986篇 |
基础医学 | 308002篇 |
口腔科学 | 62009篇 |
临床医学 | 198920篇 |
内科学 | 439224篇 |
皮肤病学 | 52139篇 |
神经病学 | 176916篇 |
特种医学 | 90351篇 |
外国民族医学 | 472篇 |
外科学 | 343050篇 |
综合类 | 49342篇 |
现状与发展 | 3篇 |
一般理论 | 656篇 |
预防医学 | 168289篇 |
眼科学 | 48655篇 |
药学 | 164984篇 |
10篇 | |
中国医学 | 4554篇 |
肿瘤学 | 123050篇 |
出版年
2018年 | 22473篇 |
2017年 | 17777篇 |
2016年 | 20938篇 |
2015年 | 23329篇 |
2014年 | 32250篇 |
2013年 | 47917篇 |
2012年 | 61194篇 |
2011年 | 65362篇 |
2010年 | 39940篇 |
2009年 | 38483篇 |
2008年 | 61018篇 |
2007年 | 65158篇 |
2006年 | 66612篇 |
2005年 | 63919篇 |
2004年 | 61173篇 |
2003年 | 59360篇 |
2002年 | 56877篇 |
2001年 | 112351篇 |
2000年 | 115727篇 |
1999年 | 96603篇 |
1998年 | 26863篇 |
1997年 | 23895篇 |
1996年 | 24665篇 |
1995年 | 24263篇 |
1994年 | 22436篇 |
1993年 | 21132篇 |
1992年 | 77101篇 |
1991年 | 74823篇 |
1990年 | 72609篇 |
1989年 | 69697篇 |
1988年 | 63865篇 |
1987年 | 62585篇 |
1986年 | 59012篇 |
1985年 | 56410篇 |
1984年 | 42027篇 |
1983年 | 35320篇 |
1982年 | 21003篇 |
1981年 | 18582篇 |
1980年 | 17565篇 |
1979年 | 37762篇 |
1978年 | 26533篇 |
1977年 | 22924篇 |
1976年 | 20600篇 |
1975年 | 22268篇 |
1974年 | 26065篇 |
1973年 | 25070篇 |
1972年 | 23481篇 |
1971年 | 21818篇 |
1970年 | 19975篇 |
1969年 | 18972篇 |
排序方式: 共有10000条查询结果,搜索用时 17 毫秒
41.
42.
Sarina A. Piha-Paul Do-Youn Oh Makoto Ueno David Malka Hyun Cheol Chung Adnan Nagrial Robin K. Kelley Willeke Ros Antoine Italiano Kazuhiko Nakagawa Hope S. Rugo Filippo de Braud Andrea Iolanda Varga Aaron Hansen Hui Wang Suba Krishnan Kevin G. Norwood Toshihiko Doi 《International journal of cancer. Journal international du cancer》2020,147(8):2190-2198
We present data from patients with advanced biliary tract cancer (BTC) receiving pembrolizumab in the KEYNOTE-158 (NCT02628067; phase 2) and KEYNOTE-028 (NCT02054806; phase 1b) studies. Eligible patients aged ≥18 years from both studies had histologically/cytologically confirmed incurable BTC that progressed after standard treatment regimen(s), measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, Eastern Cooperative Oncology Group performance status 0/1, and no prior immunotherapy. Programmed death ligand 1 (PD-L1)-positive tumors were required for eligibility in KEYNOTE-028 only. Patients received pembrolizumab 200 mg every three weeks (KEYNOTE-158) or 10 mg/kg every two weeks (KEYNOTE-028) for ≤2 years. Primary efficacy endpoint was objective response rate (ORR) by RECIST v1.1. Response assessed by independent central review is reported. KEYNOTE-158 enrolled 104 patients and KEYNOTE-028 enrolled 24 patients. Median (range) follow-up was 7.5 months (0.6-34.3) in KEYNOTE-158 and 5.7 months (0.6-55.4) in KEYNOTE-028. In KEYNOTE-158, ORR was 5.8% (6/104; 95% CI, 2.1%-12.1%); median duration of response (DOR) was not reached (NR) (range, 6.2-26.6+ months). Median (95% CI) OS and PFS were 7.4 (5.5-9.6) and 2.0 (1.9-2.1) months. Among PD-L1-expressers (n = 61) and PD-L1-nonexpressers (n = 34), respectively, ORR was 6.6% (4/61) and 2.9% (1/34). In KEYNOTE-028, ORR was 13.0% (3/23; 95% CI, 2.8%-33.6%); median DOR was NR (range, 21.5-53.2+ months). Median (95% CI) OS and PFS were 5.7 (3.1-9.8) and 1.8 (1.4-3.1) months. Grade 3 to 5 treatment-related adverse events occurred in 13.5% of patients in KEYNOTE-158 (no grade 4; grade 5 renal failure, n = 1) and 16.7% in KEYNOTE-028 (no grade 4/5). In summary, pembrolizumab provides durable antitumor activity in 6% to 13% of patients with advanced BTC, regardless of PD-L1 expression, and has manageable toxicity. 相似文献
43.
Balta Sabah Emirtekin Emrah Kircaburun Kagan Griffiths Mark D. 《International journal of mental health and addiction》2020,18(3):628-639
International Journal of Mental Health and Addiction - One of the relatively new negative consequences of smartphone use is “phubbing” (snubbing someone while an individual checks their... 相似文献
44.
45.
Samir Gupta MD MDCS AGAF Balambal Bharti MBBS MPH PhD Dennis J. Ahnen MD Daniel D. Buchanan PhD Iona C. Cheng PhD MPH Michelle Cotterchio PhD Jane C. Figueiredo PhD Steven J. Gallinger MD MSc Robert W. Haile DrPH MPH Mark A. Jenkins PhD Noralane M. Lindor MD Finlay A. Macrae MD AGAF Loïc Le Marchand MD PhD Polly A. Newcomb PhD MPH Stephen N. Thibodeau PhD Aung Ko Win MBBS MPH PhD Maria Elena Martinez PhD 《Cancer》2020,126(13):3013-3020
46.
Aliyah Hussein Kiran Sran Imran Ali Janine Woellner Helen Wilcox Stephen D. Marks Helen Jones Chris Callaghan 《Pediatric transplantation》2020,24(4)
Transplant ureteric stent insertion reduces the incidence of MUCs, but it is not known whether routine PSRGU is needed to detect unmasked MUCs. This study evaluated whether routine PSRGU in the pRTR is a useful tool to identify MUCs before they become clinically apparent. A retrospective analysis was undertaken of the clinical outcomes following elective stent removal from pediatric kidney‐only transplant recipients at two London centers between 2012 and 2016. Our policy was to perform PSRGU either routinely or urgently if there were concerning symptoms or biochemical evidence of renal allograft dysfunction. Elective stent removal was performed in 86% (97 of 113 pRTR), and 75 (77%) of whom had routine PSRGU at a median (IQR) of 6 (2‐8) days after stent removal. There were changes to management in 3 (4%) of pRTR with PSRGU identifying no MUC. Nineteen patients (25%) had urgent PSRGU, most commonly due to renal allograft dysfunction, at a median (IQR) of 5.5 (2.7‐12.3) days after stent removal. Of these, two pRTR required ureteric intervention. For our current practice of removing transplant stents at 4‐6 weeks post‐transplantation, our study has found no evidence to support routine PSRGU after elective stent removal. 相似文献
47.
Peter Düking Christoph Zinner Jennifer L. Reed Hans-Christer Holmberg Billy Sperlich 《Scandinavian journal of medicine & science in sports》2020,30(12):2291-2304
Monitoring variations in the functioning of the autonomic nervous system may help personalize training of runners and provide more pronounced physiological adaptations and performance improvements. We systematically reviewed the scientific literature comparing physiological adaptations and/or improvements in performance following training based on responses of the autonomic nervous system (ie, changes in heart rate variability) and predefined training. PubMed, SPORTDiscus, and Web of Science were searched systematically in July 2019. Keywords related to endurance, running, autonomic nervous system, and training. Studies were included if they (a) involved interventions consisting predominantly of running training; (b) lasted at least 3 weeks; (c) reported pre- and post-intervention assessment of running performance and/or physiological parameters; (d) included an experimental group performing training adjusted continuously on the basis of alterations in HRV and a control group; and (e) involved healthy runners. Five studies involving six interventions and 166 participants fulfilled our inclusion criteria. Four HRV-based interventions reduced the amount of moderate- and/or high-intensity training significantly. In five interventions, improvements in performance parameters (3000 m, 5000 m, Loadmax, Tlim) were more pronounced following HRV-based training. Peak oxygen uptake () and submaximal running parameters (eg, LT1, LT2) improved following both HRV-based and predefined training, with no clear difference in the extent of improvement in . Submaximal running parameters tended to improve more following HRV-based training. Research findings to date have been limited and inconsistent. Both HRV-based and predefined training improve running performance and certain submaximal physiological adaptations, with effects of the former training tending to be greater. 相似文献
48.
49.
50.